Bringing life to vaccine strategy.
A boutique intelligence firm sitting between vaccine candidate and market. Founded in the UK in 2007, we blend disease insight, epidemiology, and commercial intelligence to drive vaccine portfolios forward.
Mapping almost every new vaccine opportunity.
MarketVIEW is a targeted assessment of vaccine opportunity at the pathogen or disease level, combining robust epidemiology with forward-looking commercial analysis. Each product includes a detailed Excel-based value and volume forecast model, alongside an executive-ready presentation summarising key insights and strategic implications.
Travel
Maternal/Pediatric
Endemic/diarrheal
- Lyme Borreliosis vaccines forecast
- Invasive non-typhoidal Salmonella (iNTS) vaccines forecast
- Group A Streptococcus vaccines forecast
- Norovirus vaccines forecast
- Dengue endemic vaccines forecast
- Nipah (Henipavirus) vaccines forecast
- Malaria vaccines forecast
- Rift Valley Fever vaccines forecast
- MERS-CoV vaccines forecast
Adolescent/STD
Hospital
Chronic/Addiction
Hepatitis
Elderly
Recent & forthcoming.
Invasive non-typhoidal Salmonella (iNTS) vaccines - forecast to 2047
iNTS is one of the most lethal bacterial infections of young children in sub-Saharan Africa, with an estimated 594,000 cases and 79,000 deaths worldwide, and there is still no licensed vaccine. Our assessment combines a registry-verified pipeline with a country-level demand and revenue forecast to 2047 across 49 sub-Saharan African countries. Register your interest ahead of publication.
Lyme borreliosis vaccines - forecast to 2040
Valneva and Pfizer's PF-07307405 narrowly missed its Phase 3 VALOR primary endpoint while showing 73-75% efficacy, and its EU application has now been validated by the EMA. The June 2020 edition was updated for travel in August 2026; the endemic-population update is in progress for Q4 2026, and the full syndicated refresh is subject to client buy-in.
New travel vaccines - segment forecast to 2040
The 2026 edition is complete and available to order. 13 marketed travel vaccines de-layered from their wider franchises across 13 origin markets - 169 anchored, confidence-graded country cells - plus 9 new product forecasts under three IATA-anchored scenarios. Includes the primary traveller survey.
Group A Streptococcus vaccines - forecast to 2045
No licensed GAS vaccine exists, yet severe disease still kills over half a million people a year - and GSK and Vaxcyte have both now entered the clinic. The 2026 edition comes as two model options: Western paediatric and older-adult indications, or developing-world rheumatic heart disease.
Global seasonal influenza market + COMBOs to 2040
Sanofi versus CSL Seqirus - who's winning the race in global differentiated vaccines? What will be the impact of mRNA, now approved as a combination in the EU? Our new global analysis has the full picture.
Strategic Vaccine & mRNA Pipeline Review
Analysis of 2,279+ Phase I–IV industry trials across 109 pathogens and 270 companies. Includes a dedicated mRNA landscape focus section covering Moderna, Pfizer, GSK, Sanofi and new entrants. June 2026 edition.
Quick reads, live on the site now.
Lyme vaccines: efficacy shown, Europe filed. Now the demand question.
LB6V delivered 73.2% efficacy in VALOR, presented at IDWeek 2026, with an EU application under EMA assessment. What it means for US and European demand - and the North American model now complete.
Read the insight →Adjuvanted flu: not just a 65+ vaccine anymore?
New CSL Seqirus US modeling makes the case for adjuvanted flu vaccines in adults 50-64, alongside the parallel Moderna and Sanofi regulatory moves into the same age band.
Read the insight →A single flu-COVID shot. Will older Americans take it?
US survey of 500+ adults 50+: 64% would accept a combination flu-COVID vaccine, but 60% didn't even know one was in development.
Read the insight →Eli Lilly enters the vaccine arena
A bolt-on M&A pipeline snapshot: Lilly's 3 acquired vaccine programmes benchmarked against 58 incumbent assets across 7 established manufacturers.
Read the insight →Five EU5 markets. One mRNA flu league table.
Modelled mRNA flu penetration to 2035 across Germany, Spain, Italy, France and the UK - three scenarios, and the access triggers that could double revenue exposure.
Read the insight →Continued growth. Emerging headwinds.
A record 5.2 billion air passengers forecast for 2026, but five structural IATA risks are moderating momentum - and reshaping travel vaccine demand.
Read the insight →Olymvax says its Staph vaccine works. The field has not seen that before.
Chengdu Olymvax's Phase 3 topline for rFSAV hit 73.25% efficacy against a 60% target - a first for Staph vaccines in twenty years, and now under challenge from an anonymous report.
Read the insight →Built around portfolio decisions, not slide formats.
Asset diligence
Mechanism, target product profile, comparator landscape, and probability-of-success framing for licensing or in-house pipeline decisions.
Indication mapping
Where adjacent vaccines, off-label use, and emerging epidemiology widen - or close - a commercial window.
Forecast review
Independent stress-test of internal forecasts: assumptions, sensitivity, payer behaviour, real-world uptake calibration.
Policy tracking
Continuous read of ACIP, JCVI, STIKO, HAS, NITAG signal - interpreted not just summarised.
Adult immunisation
Pneumococcal, RSV, zoster, influenza, COVID combinations - where adult uptake is being made or lost.
Maternal & paediatric
Schedule integration, programmatic constraints, equity dynamics across high- and low-income geographies.
Tender & access
UNICEF, PAHO, Gavi, EU joint procurement and national tender behaviour - and what it means for net price.
Travel vaccines
Expert insights on global travel immunization strategy, risk, and market analytics.
A vaccine intelligence identity, refreshed.
I believe vaccines are one of humanity's greatest achievements. Few innovations have saved as many lives, across every age group and every part of the world. That belief is what led me to found VacZine Analytics in 2007, to help our clients build the evidence, confidence, and momentum needed to bring the next generation of vaccines forward.
VacZine Analytics has been working alongside the vaccine industry since 2007 - long enough to remember when adult immunisation was a slide-deck afterthought, and long enough to know which questions are actually load-bearing. We are deliberately boutique: tight teams, deep files, no junior layer in front of the analyst.
Request a briefing or report sample.
A short three-step request. We respond within two working days from a UK address. Lawful basis: consent (GDPR Art. 6(1)(a)).
Curious about cost first? See indicative MarketVIEW pricing.
Common questions, briefly answered.
How do you use AI in your research process?
We use AI tools selectively to support parts of our research and modelling work, helping our analysts work more efficiently. This includes our DemandENGINE™ forecasting technology, where analysts set and review every assumption. AI does not make decisions in our studies. Every analytical step, assumption and conclusion is decided by a human analyst, and anything produced with AI assistance is checked by an analyst before it informs a forecast or reaches a client. Our forecasts and recommendations remain the independent judgement of our analysts.
What does working with VacZine Analytics actually look like?
Usually one of two shapes: a syndicated report (single copy access) or a bespoke project with a defined deliverable and timeline. Both start with a 30-minute call so we can scope properly. All engagements run under our .
Do you publish public reports?
Selectively, but mainly through shorter white papers or expert pieces. Our syndicated catalogue reports which cover our focus therapeutic areas are licensable on a non-exclusive, non-transferable basis. Most other work is single-client and confidential. Ask for the catalogue and we'll send what's currently live.
How does VacZine Analytics report licensing work?
We license our syndicated reports on a non-exclusive, non-transferable basis. This is standard practice across market intelligence and data providers, and it means clients have broad rights to use the content internally for their own business purposes, but do not acquire ownership of the underlying intellectual property or the right to redistribute it. “Non-exclusive” allows us to license the same report to multiple organisations, keeping prices at a sustainable level, while “non-transferable” ensures that only the contracting client (and its authorised personnel) may access the materials, not external agencies, partners, or other third parties.
How is your work different from a big-three consultancy?
We're deliberately small and vaccine-only. There's no junior layer in front of the analyst, no rotating staffing, and no sector-tourist framing. We've been doing this since 2007 - the institutional memory is the product.
What about data and confidentiality?
Standard mutual NDA before any client material is shared. Our data infrastructure runs on UK-hosted services with role-based access. See the for what we collect on this site itself.
How do you handle policy / regulatory references?
Public-domain meetings, slide decks, and policy minutes - ACIP, JCVI, STIKO, HAS, EMA, FDA, WHO SAGE, MHRA - are read in primary form, not via news summaries. Trial registry IDs are checked against ClinicalTrials.gov and EU CTR. Sponsorship trademarks are used for identification only - see the credits line at the foot of the page.